These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 26616881)
1. Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product. Hromadkova L; Kolarova M; Jankovicova B; Bartos A; Ricny J; Bilkova Z; Ripova D J Neuroimmunol; 2015 Dec; 289():121-9. PubMed ID: 26616881 [TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein. Smith LM; Coffey MP; Klaver AC; Loeffler DA Int Immunopharmacol; 2013 Aug; 16(4):424-8. PubMed ID: 23669333 [TBL] [Abstract][Full Text] [Related]
3. Characterization of isolated tau-reactive antibodies from the IVIG product, plasma of patients with Alzheimer's disease and cognitively normal individuals. Krestova M; Hromadkova L; Bilkova Z; Bartos A; Ricny J J Neuroimmunol; 2017 Dec; 313():16-24. PubMed ID: 29153604 [TBL] [Abstract][Full Text] [Related]
4. Specific binding of intravenous immunoglobulin products to tau peptide fragments. Smith LM; Coffey MP; Loeffler DA Int Immunopharmacol; 2014 Aug; 21(2):279-82. PubMed ID: 24859060 [TBL] [Abstract][Full Text] [Related]
5. ELISA measurement of specific antibodies to phosphorylated tau in intravenous immunoglobulin products. Loeffler DA; Klaver AC; Coffey MP Int Immunopharmacol; 2015 Oct; 28(2):1108-12. PubMed ID: 26330100 [TBL] [Abstract][Full Text] [Related]
6. Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation. Esteves-Villanueva JO; Trzeciakiewicz H; Loeffler DA; Martić S Biochemistry; 2015 Jan; 54(2):293-302. PubMed ID: 25545358 [TBL] [Abstract][Full Text] [Related]
7. Natural human antibodies to amyloid beta peptide. Szabo P; Relkin N; Weksler ME Autoimmun Rev; 2008 Jun; 7(6):415-20. PubMed ID: 18558354 [TBL] [Abstract][Full Text] [Related]
8. Purification of Natural Antibodies Against Tau Protein by Affinity Chromatography. Krestova M; Hromadkova L; Ricny J Methods Mol Biol; 2017; 1643():33-44. PubMed ID: 28667528 [TBL] [Abstract][Full Text] [Related]
9. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies. Klaver AC; Coffey MP; Smith LM; Loeffler DA Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186 [TBL] [Abstract][Full Text] [Related]
10. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Klaver AC; Finke JM; Digambaranath J; Balasubramaniam M; Loeffler DA Int Immunopharmacol; 2010 Jan; 10(1):115-9. PubMed ID: 19840873 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of antigen specificities in the monomeric and dimeric fractions of intravenous immunoglobulin. Miescher SM; Schaub A; Ghielmetti M; Baumann M; Vogel M; Bolli R; Stadler B Ann N Y Acad Sci; 2005 Jun; 1051():582-90. PubMed ID: 16126998 [TBL] [Abstract][Full Text] [Related]
12. Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. Szendrei GI; Lee VM; Otvos L J Neurosci Res; 1993 Feb; 34(2):243-9. PubMed ID: 7680727 [TBL] [Abstract][Full Text] [Related]
13. Use of a human recombinant immunoglobulin G1 CH3 domain as a probe for detecting alternatively folded human IgG in intravenous Ig products. Guhr T; Derksen N; Aalberse R; Rispens T J Pharm Sci; 2012 Mar; 101(3):978-86. PubMed ID: 22102504 [TBL] [Abstract][Full Text] [Related]
14. Aβ anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration. Loeffler DA; Klaver AC; Coffey MP Autoimmunity; 2015 Jun; 48(4):196-200. PubMed ID: 25392130 [TBL] [Abstract][Full Text] [Related]
15. Characterization of immunoglobulin G fragments in liquid intravenous immunoglobulin products. Diemel RV; ter Hart HG; Derksen GJ; Koenderman AH; Aalberse RC Transfusion; 2005 Oct; 45(10):1601-9. PubMed ID: 16181211 [TBL] [Abstract][Full Text] [Related]
17. Traces of pFc' in IVIG interact with human IgG Fc domains and counteract aggregation. Rispens T; Himly M; Ooievaar-De Heer P; den Bleker TH; Aalberse RC Eur J Pharm Sci; 2010 Apr; 40(1):62-8. PubMed ID: 20211252 [TBL] [Abstract][Full Text] [Related]
18. Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo. Cattepoel S; Gaida A; Kropf A; Nolte MW; Bolli R; Miescher SM PLoS One; 2016; 11(8):e0161826. PubMed ID: 27561008 [TBL] [Abstract][Full Text] [Related]
19. Self-reactivity in the dimeric intravenous immunoglobulin fraction. Schaub A; Wymann S; Heller M; Ghielmetti M; Beleznay Z; Stadler BM; Bolli R; Miescher S Ann N Y Acad Sci; 2007 Sep; 1110():681-93. PubMed ID: 17911483 [TBL] [Abstract][Full Text] [Related]
20. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Rosenmann H; Meiner Z; Geylis V; Abramsky O; Steinitz M Neurosci Lett; 2006 Dec; 410(2):90-3. PubMed ID: 17095156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]